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The ability of circulating blood monocytes to express C1q receptors (cC1qR and gC1qR)
as well as to synthesize and secrete the classical pathway proteins C1q, C1r, and C1s
and their regulator, C1-INH is very well established. What is intriguing, however, is that,
in addition to secretion of the individual C1 proteins monocytes are also able to display
macromolecular C1 on their surface in a manner that is stable and functional. The cell sur-
face C1 complex is presumably formed by a Ca2+-dependent association of the C1r2·C1s2
tetramer to C1q, which in turn is anchored via a membrane-binding domain located in the
N-terminus of its A-chain as shown previously. Monocytes, which circulate in the blood
for 1–3 days before they move into tissues throughout the body, not only serve as precur-
sors of macrophages and dendritic cells (DCs), but also fulfill three main functions in the
immune system: phagocytosis, antigen presentation, and cytokine production. Since the
globular heads of C1q within the membrane associated C1 are displayed outwardly, we
hypothesize that their main function – especially in circulating monocytes – is to recognize
and capture circulating immune complexes or pathogen-associated molecular patterns in
the blood. This in turn may give crucial signal, which drives the monocytes to migrate into
tissues, differentiate into macrophages or DCs, and initiate the process of antigen elimina-
tion. Unoccupied C1q on the other hand may serve to keep monocytes in a pre-dendritic
phenotype by silencing key molecular players thus ensuring that unwarranted DC-driven
immune response does not occur. In this paper, we will discuss the role of monocyte/DC-
associated C1q receptors, macromolecular C1 as well as secreted C1q in both innate and
acquired immune responses.
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INTRODUCTION
Monocytes serve a critical role in adaptive and innate immunity
not only by serving as precursors of macrophages and myeloid
dendritic cells (DCs), but also by their function in phagocyto-
sis, antigen processing, and presentation, as well as secretion of
pro- and anti-inflammatory cytokines. Monocytes are produced
by the bone marrow from hematopoietic stem cell precursors
called monoblasts, and circulate in the bloodstream for about
3 days before they migrate into tissues throughout the body where
they develop into different types of macrophages and DCs (1,
2). Although their inherent plasticity allows them to develop into
various types and subtypes, three major types of blood mono-
cyte subpopulations are recognized: the classical monocyte or
CD14++ CD16–, which expresses high level of the LPS recep-
tor (CD14) but no expression of Fc receptor (CD16), and the
Abbreviations: cC1qR, receptor for the collagen-like region of C1q; DC, dendritic
cell; gC1qR, receptor for the globular heads of C1q; iDC, immature DC; mDC,
mature DC.
non-classical monocyte or CD14+CD16++ characterized by low
level expression of CD14 but higher level of CD16 expression. The
third is an intermediate between the two,which expresses high level
CD14 but low level CD16 (CD14++CD16+) and is postulated to
serve as a transitory link in the maturation process of the classical
monocyte into the activated, non-classical monocyte (1, 2). The
various monocyte types have been shown to exhibit distinct phe-
notype and function. Upon activation with microbial antigens, the
non-classical monocytes are activated to produce high amounts of
pro-inflammatory cytokines including tumor necrosis factor and
IL-12 and exhibit higher potency in antigen presentation.
One of the major functions of blood monocytes is to eliminate
antibody- or complement-opsonized microbes through either
phagocytosis or by binding directly to the pathogen via pattern-
recognition receptors (PRRs) that recognize pathogen-associated
molecular ligands (3). Emerging among these PRRs are cC1qR
and gC1qR, which in addition to their primary ligand, C1q, can
also independently recognize a vast array of plasma proteins as
well as pathogen-associated molecular ligands (4, 5). Moreover,
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monocytes express on their surface an intact macromolecular C1
as well as C1-INH (6, 7) with the globular heads free to recognize
antigens. However, despite the available body of evidence showing
the presence of macromolecular C1 on the surface of circulating
blood monocytes (7), not much is known about its physiologic
function. Based on the available data, we postulate that C1q –
within the C1 complex expressed on circulating monocytes – may
serve not only as a molecular sensor of danger but also as a mol-
ecular guarantor of steady state. Thus, while in the steady state,
C1q within the C1 complex would regulate early processes that
maintain cells in the monocyte or monocyte-like lineage, (innate
immunity); recognition of “danger” would impart a license that
drives monocytes toward the DC lineage (adaptive immunity).
Deficiency in C1q therefore would disrupt this equilibrium.
DENDRITIC CELLS AND AUTOIMMUNE DISEASES
Dendritic cells are a complex lineage of antigen presenting cells
(APCs) that orchestrate a variety of immune responses (3, 8–
14). Although B and T cells are known to be the mediators of
acquired immunity, their function is under the control of DCs.
DCs in various stages of maturity capture, process and present
antigens, express lymphocyte co-stimulatory molecules when acti-
vated, migrate to lymphoid organs, and secrete cytokines to initiate
immune response (9). While B cells, the precursors of antibody-
secreting cells, can directly recognize native antigen through their
B-cell receptors, T lymphocytes need the antigen to be processed
and presented to them by APCs such as DCs. The T cell antigen-
receptors (TCRs) recognize fragments of the processed antigens
bound to MHC molecules on the surface of DCs (9). The peptide-
binding molecules on the APC are of two types: MHC class I
(MHC I), which stimulates cytotoxic CD8+ T cells, and MHC
class II (MHC II), which stimulates helper CD4+ T cells (8). A
second co-stimulatory signal that is critical for T cell activation is
the interaction of CD28 on the T cell and CD80/CD86 on the APC
such as DC. In addition to their ability to activate lymphocytes,
DCs can also tolerize T cells to self-antigens by a variety of mech-
anisms including the production of regulatory cytokines such as
IL-10 and the induction of regulatory T cells (11, 14).
Dendritic cell precursors circulate in the bloodstream as mono-
cytes, which are continuously generated from bone marrow prog-
enitors. Migration into non-lymphoid organs induces differenti-
ation of DC precursors into DCs that become resident tissue cells
of the interstitium of peripheral organs or skin (9). These tissue-
resident DCs are thought to be in an immature state [immature
DCs (iDCs)] and are specifically characterized by high phagocytic
activity and the ability to capture self and foreign antigens. The
presence of specific lectins, such as DC-SIGN, Langerin, and man-
nose receptors on their surface allows iDCs to recognize invading
bacteria or viruses (10, 13). Moreover, the expression of molecules
such as αvβ5 integrin and CD91 enables them to recognize and
engulf self-antigens including those associated with apoptotic cells
(10). Therefore, imDCs can interact with self-components, and
virtually every antigen present in the periphery can be processed
after engulfment and presented as peptide–MHC complexes on the
DC surface (8, 11). Fortunately, tolerogenic mechanisms exist to
prevent inappropriate autoimmune responses. Presumably, under
steady state conditions DCs remain immature and start migrating
towards lymph nodes upon partial activation signaling. Once
they have reached the T cell area, these semi-mature DCs may
induce tolerance by numerous mechanisms (3, 11, 14). In contrast,
when DCs encounter a peripheral microenvironment character-
ized by pro-inflammatory factors and antigenic material, massive
migration and maturation is triggered by molecules such as LPS,
bacterial DNA, and double stranded RNA, which are recognized by
specific Toll-like receptors (3, 12). Cytokines such as TNF-α and
IL-1β found in the inflammatory compartment are also impor-
tant participants in the DC maturation/activation process (9).
The maturation of DCs is associated with the up-regulation of
co-stimulatory molecules such as CD40, CD80, CD86, and CD58,
secretion of cytokines, such as TNF-α, IL-6, and IL-12p70, the
loss of endocytic phagocytic receptors, high levels of MHC I, II,
CD83, and acquisition of high cellular mobility (13). The mature
DCs migrate to the T cell areas of local lymph nodes where they
are retained via specific chemokine interactions involving CCR7.
Subsequent screening events result in engagement of the appro-
priately matched T cell-MHCI/MHCII receptors. Priming of naïve
CD4+ T cells takes place when DCs engage CD40L. Because of
their unique ability to initiate immune responses against invading
pathogens as well as against peptides derived from self-proteins,
DCs play an important role in the development of autoim-
mune diseases. However, a variety of mechanisms impact on the
immunogenicity of DC in order to prevent autoimmune responses
including local factors that facilitate decisions about the nature and
subset of T cell response (15–18). The various signals that influ-
ence the DC are not yet fully elucidated, but these signals are likely
to depend on the type and dose of antigen, the microenvironment
of the DC–antigen encounter, the number, subset, and phenotype
of the DC involved, the microenvironment of the secondary lym-
phoid organs where the antigen is presented, and finally the local
synthesis of modulatory proteins including complement proteins,
such as C1q, and its C1q receptors each of which is capable of
recognizing and capturing self or non-self antigens.
EXPRESSION OF C1 AND C1q RECEPTORS ON MONOCYTES
AND DENDRITIC CELLS
The synthesis of the subunits of the C1 complex (C1q, C1s, C1r),
and its regulator C1 inhibitor (C1-INH) by human monocytes
has been shown independently by several investigators (6, 19–24).
However, the expression of the intact macromolecular C1 on the
cell surface of monocytes and DCs has been described only recently
(7). The first indication of the existence of a membrane form of C1
was intimated by the finding that monocyte-derived macrophages
were able to synthesize and express a membrane anchored form of
C1q (25). Furthermore, these original experiments showed that:
(i) the surface expressed C1q was tightly and irreversibly anchored
into the cell surface membrane with its globular heads displayed
outwardly as evidenced by the fact that it was able to bind Fc,
polyanions, the lipid A part of LPS, Gram-negative bacteria such
as S. minnesota, as well as porins (outer membrane bacterial pro-
teins); (ii) the A-chain of C1q contains amino acid sequences with
properties characteristic of an integral type II membrane protein;
and (iii) the surface molecule could only be liberated by detergent
or repeated freeze-thawing (26, 27). However, these observations
presumed that macrophages and not their monocyte precursors
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FIGURE 1 | Circulating blood monocytes express C1 and C1qRs. (1)
Membrane anchored C1q displays its globular heads free to interact with
antigens or immune complexes. (2) Some of the membrane anchored C1q
is cleaved off and secreted into the pericellular milieu and is able to bind to
the cell surface via gC1qR.The C1q figure was obtained from Gérard Arlaud.
were able to express C1q on their surface. Using more sensitive
assays and antibodies, recent experiments from our laboratory
have shown that non-stimulated circulating blood monocytes are
also able to both synthesize and express all of the components of
C1 (C1q, C1r, C1s) as well as C1-INH (7). The C1 complex is pre-
sumably assembled around the C1q molecule in a manner that is
similar to the C1 complex in plasma,with the C1q molecule serving
as an anchored backbone to which the C1r2·C1s2 tetramer is linked
via Ca2+ ions. Such a configuration, which is similar to the natural
configuration of plasma C1 (Figure 1) would allow the exposure
of the globular heads for immune complex binding or antigen
recognition and complement activation. This assumption is also
corroborated by the finding that the U937 expressed C1, is able to
activate complement (7), and this activation is closely controlled
by C1-INH, present on or near the cell surface (6). Collectively, the
data suggest that the surface-associated C1 complex can initiate
complement activation in response to an extracellular Ag and thus
may represent the earliest response to either pathogen-associated
or modified self-associated danger signals in blood.
The expression of C1q on monocytes is dependent on the matu-
ration stage (Figure 2). While activated monocytes (macrophages)
and immature DCs express elevated levels of C1q, this ability is lost
when iDCs transition into mature DCs (mDCs) (28, 29). Inter-
estingly, this expression profile is also mimicked by both C1q
receptors (cC1qR and gC1qR), which in turn are co-localized
with C1q and DC-SIGN on iDCs suggesting that C1q/gC1qR
may regulate DC differentiation and function through the DC-
SIGN-mediated induction of cell-signaling pathways (30). While
inflammatory cytokines and LPS, which induce maturation of
DCs, downregulate surface expression of both C1qR molecules,
cytokines, and drugs such as IL-10, TNFα, or dexamethasone, that
keep DCs phenotypically and functionally immature significantly
upregulate the expression of both C1qRs (28).
The significance of C1q in the development of autoimmune dis-
eases such as systemic lupus erythematosus (SLE) has been known
for many years (31–33), and its potential role in tolerance induc-
tion has been proposed (34, 35). However, neither the mechanism
by which C1q determines the activation thresholds of B and T
cells nor how C1q deficiency causes incomplete maintenance of
peripheral tolerance is clearly understood. The fact that C1q is co-
localized with a number of surface molecules such as DC-SIGN,
gC1qR, and cC1qR-implies that these molecules may collaborate
in antigen recognition and processing (30).
C1 DEFICIENCY AND SLE
Systemic lupus erythematosus – a prototype of a systemic autoim-
mune disease – affects close to three-quarters of a million indi-
viduals in the US and a much higher number worldwide with
a frequency that varies by race and ethnicity with higher rates
reported among Black and Hispanic people (36). Although it is
a multifactorial disease, there is an overwhelming clinical evi-
dence showing that homozygous deficiency in any of the classical
pathway proteins – C1q, C1r, C1s, C4, and C2 – predisposes an
individual to develop SLE and other autoimmune diseases such
as rheumatoid arthritis (RA) (31, 33, 37). Among these proteins,
C1q takes a prominent stage in significance as homozygous defi-
ciency or hereditary deficiency due to mutation in the C1q gene
is regarded as a strong susceptibility factor for the development of
SLE (31, 33). The majority (≥95%) of the known individuals with
C1q deficiency are known to have developed clinical syndromes
closely related to SLE (31, 33, 38, 39). Interestingly, the majority
of the circulating antibodies in SLE are against “modified self”
or intracellular proteins (nuclear or cytoplasmic), suggesting that
C1q may play an important role in the regulation and processing
of these antigens.
There has been an exponential increase in recent years explor-
ing the possibility that C1q is a major link between innate and
acquired immunity. Some of these studies have been made possible
in part due to the availability of C1q−/− animal models (40). As an
archetypal pattern-recognition molecule with the ability to sense a
wide variety of targets, C1q can engage a broad range of ligands –
ranging from pathogen-associated molecular ligands (non-self) to
damage-associated molecular targets (altered self) – including“eat
me” signals such as self DNA and phosphatidylserine, which are
the first structures exposed at the apoptotic cell surface (41–45).
These interactions are able to trigger a multiplicity of immuno-
logic functions, which by and large are beneficial to the host. It
is not therefore surprising that deficiency in C1q leads to various
diseases including otitis media, meningitis, pneumonia (31, 34, 37)
as well as autoimmune diseases, such as SLE (31, 46, 47). Several
reports have shown that C1q can bind via its globular“heads”to the
surface of apoptotic cells (44, 47); and the common autoantigens
targeted in SLE are found in high concentrations on the surface
of apoptotic cells (44, 47). However, although it is clear that C1q
and its receptors play a role in removal of self-waste (44, 47–50)
the existence of functionally redundant pathways for apoptotic
body clearance gives credence to the postulate that autoimmunity
arising from diminished C1q activity could reflect another role of
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FIGURE 2 | Expression of C1q and C1qRs is maturation dependent. Circulating monocytes express both C1 and C1qRs, which increase during the
monocyte to iDC transition in the presence of self- or foreign-danger signals. Fully mature DCs, however, express little or no C1q, low gC1qR but high cC1qR.
C1q in maintaining tolerance (34). Thus, while C1q could provide
active protection from autoimmunity by silencing key molecu-
lar markers or regulating autoreactive immune cells, its absence
or defective expression could lead to a loss of peripheral toler-
ance as a cumulative result of impaired apoptotic cell clearance
in conjunction with negative signaling. For example, incubation
of C1q with T cells has been shown to inhibit T cell prolifera-
tion presumably by binding to gC1qR on the T cell surface (51)
since this activity is mimicked by incubation of cells with mAb
60.11, which recognizes the C1q binding site on gC1qR. Further-
more, although its role is not precisely known, soluble gC1qR
is able to bind CD4 thereby blocking HIV-1 viral entry into T
cells (52). More importantly, because of its heterotrimeric nature
and oligomeric structure – with two distinct structural and func-
tional domains (gC1q and cC1q) – C1q is also able to interact
with cell surface receptors via either its cC1q or gC1q domains.
Similar to C1q, the C1q receptors are differentially expressed as
monocytes go through the maturation process to become mDCs
(35). When monocytes are cultured in the presence or absence
of GM-CSF+ IL-4, nearly all monocyte-derived DCs expressed
gC1qR on day 0 (Figure 3B), while cC1qR was more variable
within the population (Figure 3A), despite the consistently ele-
vated expression of its putative surface partner, CD91 (Figure 3C).
Even though there was a modest reduction in gC1qR+ cells by day
4 (Figure 3B), the percent of cC1qR expression increased com-
pared to day 0 (Figure 3A). Furthermore, mean fluorescence index
(MFI) analysis revealed that the amount of cC1qR was dramati-
cally amplified after day 2 (Figure 3D), whereas the amount of
gC1qR remained at relatively steady levels (Figure 3E). Thus, at
the precise period (~day 3) corresponding to firm commitment to
the DC lineage there is an inverse correlation between gC1qR and
cC1qR expression on the cell surface, which in turn may influence
the nature and specificity of the cells’ response to C1q. Interest-
ingly, despite the increase in cC1qR expression, its surface partner,
CD91, was gradually reduced during the culture period, indicating
that alternate partners for cC1qR are present upon commitment to
the DC lineage (Figures 3C,F). Taken together, these data suggest
that the regulatory effects of C1q on DC differentiation and func-
tion may depend on specific C1q/C1qR interactions; and these
interactions may in turn control the transition from the monocyte
state (innate immunity) toward the professional APC state (adap-
tive immunity). The observation that soluble C1q functions as a
“molecular switch” during the narrow window – i.e., at the precise
period (~day 3) corresponding to firm commitment to the DC lin-
eage – of monocyte to DC transition (35) not only explains why
C1q is primarily synthesized, expressed, and secreted by potent
APCs, but also why its absence can impair antigen uptake and
tolerance.
On the basis of the available data and our own recent
findings (35), we speculate that soluble C1q induces inflam-
matory responses by binding through its gC1q to pathogen-
associated molecular patterns (PAMPs) and to modified self anti-
gens (DAMPs), and stimulates phagocytic cells through interac-
tions of its cC1q domain with cC1qR. According to this hypothesis,
a normal response to “danger” would involve up-regulation of
cC1qR on iDC to ensure uptake of noxious agents utilizing the
Ag-retrieving functions of C1q (44, 48). In the context of inflam-
matory stimuli, DC maturation would ensue allowing adaptive
immune responses against the initiating agent. In contrast, C1q
that is free of antigenic cargo (i.e., in the absence of danger) does
not support full commitment to the DC lineage, and instead keeps
them in a monocytic phenotype as represented during steady state.
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FIGURE 3 | Maturation dependent expression of C1qRs. C1q receptors
show varied expression on mono-DC precursors. Mononuclear cells were
cultured in the presence of GM-CSF+ IL-4, and collected and analyzed on
days 0–4 for the expression of cC1qR (A,D), gC1qR (B,E), and CD91 (C,F) for
both percent expression (A–C) and MFI (D–F). (A) The percent of cC1qR
expression was variable on monocytes, but by day 2 nearly all monocyte-DCs
had the receptor on their surface. (B) On day 0, gC1qR was present on
almost all the cells, and its expression was only slightly reduced by day 4.
(C) Monocytes expressed CD91 on their surface, but the percentage of
CD91+ cells was significantly reduced by day 3 and 4. (D) Mean fluorescence
analysis revealed that cC1qR expression was dramatically amplified by day 3
and 4. (E,F) gC1qR and CD91 MFIs remained at relatively steady levels
throughout the days. Experiments were gated on DR+ cells, *p<0.05,
**p<0.01 (n≥4) [adapted from Ref. (35)].
Therefore, during normal physiology, return to steady state levels
of C1q/C1qR on monocytes and/or DC precursors would resume
once pathogen/danger has been cleared (Figure 4).
Similar to the suppressive effect of C1q on T cells acting through
gC1qR/C1q interactions (51, 53), we hypothesize that the regula-
tory effects of C1q on monocyte/DC precursors may occur via
engagement of gC1q. Due to the swift nature of the monocyte
to DC transition, regulatory effects of a C1q/C1qR system would
occur within a narrow time frame and would be influenced by the
microenvironment (steady state or infection or inflammation).
The dichotomy of the two apparently opposing roles of C1q in
turn are a result of the binding orientation of C1q – heads versus
tails – and the specific receptors engaged (gC1qR versus cC1qR)
on the cell surface. Such duality of function would be very similar
to the role of surfactant proteins (Sp)-A and Sp-D in the lung,
which help maintain the steady state environment via binding to
the ITIM-containing SIRPα through their globular head domains
or initiate ingestion and pro-inflammatory responses through the
collagenous tails and cC1qR (calreticulin)/CD91 (54). Further-
more, although the significance of these motifs has yet to be
elucidated, another intriguing observation in this context is the
presence of dueling ITAM/ITIM motifs around the tyrosines at
positions 224 and 236, respectively on gC1qR, which is unique for
a molecule that is both an intracellular protein and a cell surface
receptor (55). The observations described above together with the
finding that there is a clear differential pattern of C1qR expres-
sion during the monocyte to DC transition (28, 35), allows us
to hypothesize that preferential engagement of distinct regions of
C1q (globular heads versus collagen tails) takes place during dif-
ferent stages of DC growth. Accordingly, the globular head domain
of the molecule would mediate regulatory effects of C1q. Since the
collagen tail of the C1q in plasma or on the cell surface would
be occupied, this association only allows the C1q subunit to bind
gC1qR and not cC1qR on the cell surface. In support, we have
found that some or all of the C1q detected on the monocyte
surface is part of the C1 complex (7). Furthermore, cC1qR has
been shown to bind C1q only when it undergoes a conformational
change (e.g., through immobilization on a surface) (56). Such
altered conformation may take place when C1q binds antigen or
immune complexes.
EFFECT OF C1q ON DC DIFFERENTIATION AND FUNCTION
The development of monocyte-derived DCs from human periph-
eral blood (PB) is marked by the rapid loss of CD14 (receptor for
LPS), up-regulation of CD11c [integrin, αx (complement com-
ponent 3 receptor 4 subunit (CR4)], HLA-DR (MHC class II),
and co-stimulatory and maturation associated molecules (such as
CD86, CD80, CD83) (57–59). Distinct subsets of DC precursor
www.frontiersin.org June 2014 | Volume 5 | Article 278 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ghebrehiwet et al. Monocyte expressed C1 and C1qRs
Unoccupied
C1q
Unoccupied
C1q
Ag binding to
C1q
Ag Loaded
C1q
Steady State Immunogenic Response
Fast transi!on
Monocyte
Semi-mDC
mDC
Monocyte
CD14hiCD11chi
HLA-DRhiCD86hi 
CD14loCD11chi
FIGURE 4 | Schematic representation of a fine-tuned balancing act. The transition from steady state to immunogenic response depends on the encounter
between an antigen and C1q.
populations have been described to arise from human PB mono-
cytes treated with GM-CSF+ IL-4. These include CD14−CD11c+,
CD14−CD11c−, and CD16±CD14+CD11c+ cells (58, 59). While
the majority of iDCs avidly ingest potentially antigenic material
as a prerequisite for an immunogenic response, failure to undergo
terminal maturation into APCs results in a potentially tolerogenic
state (8, 11). Targeting of various uptake receptors, notably of C-
type lectin receptors (e.g. DC-SIGN, Langerin, BDCA-2, Dectin-2,
etc.) by self-derived Ag on iDCs leads to tolerance by default (8,
11), whereas pathogen-derived Ag might simultaneously signal
through TLRs and C-type lectins, thus induce immunity (8, 11).
Although somewhat contradictory to the findings of oth-
ers, which showed that C1q induces maturation of DCs
(60), recent data from our laboratory (35) show that: (i)
even in the presence of DC growth factors, exogenously
added C1q is able to inhibit the expression of monocyte-
derived DC maturation markers such as CD86, a required
co-stimulatory molecule for T cell activation (Figures 5A,B);
(ii) C1q promotes the development of distinct iDC subsets
CD14hiCD11chiCD16±HLA-DRhiCD86dim (Figures 5C,D) com-
pared to CD14−CD11chiCD16−HLA-DRhiCD86hi cells, which
develop without C1q. The decreased expression of maturation
dependent markers on C1q treated versus untreated cells sub-
stantiates the notion that C1q alters monocyte to DC differentia-
tion. In addition to these observations, our previously published
results (7, 35) indicate that Ag-free, extracellular C1q exerts a
regulatory signaling function through engagement of the glob-
ular heads by surface gC1qR and thus modulate the differentia-
tion of monocyte-DC precursors and induce the development of
CD14hiCD11chiCD16+/− cells. Therefore, the decreased expres-
sion of DC maturation dependent markers and the increased
expression of monocyte associated surface molecules in the
presence of C1q support the concept that the developing cells
acquire features of both monocyte and DC. Because C1q is struc-
turally similar to SP-A and SP-D, it might also perform a dual
function in that it may help maintain the steady state environment
via binding to ITIM-containing surface molecules on cells (54, 61)
including gC1qR through its globular head domains. Accordingly,
occupancy of the gC1q by foreign Ag would induce a conforma-
tional change (56) thereby making the collagen tail available for
binding to cC1qR. The ensuing cell differentiation and signaling
events would thus support rapid DC maturation and immune acti-
vation. Conversely, self-derived Ag bound C1q might relay signals
through C1q or C-type lectin receptors only, thus inducing a strong
tolerogenic response, resulting in development of tolerogenic DC
and Treg activation.
INSIGHTS IN TO THE MECHANISMS OF C1q-MEDIATED
MONOCYTE/DC SIGNALING
To date, the information available on the signaling events reg-
ulated by C1q in DCs is very limited. Some studies using
murine bone marrow-derived DCs, have shown that C1q treat-
ment suppresses IL-12 production, and reduces the phosphory-
lation of p38, ERK1/2, c-Jun N-terminal kinase, and extracellular
signal-regulated kinase after stimulating the cells with LPS, CpG
oligodeoxynucleotides, or anti-CD40 antibodies (62, 63). This is
contrary to the findings by others that C1q induces maturation
of DCs and secretion of IL-12 and TNF-α and elevated their
T cell stimulating capacity (60). However, a definitive mecha-
nism that mediates C1q signaling in human DCs has not been
described. Understanding the molecular mechanisms of how C1q
regulates adaptive immune functions via iDCs in the absence of
infection or inflammation is therefore highly significant. Since
our data indicate that CD14 levels are markedly increased on
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FIGURE 5 | C1q delays GM-CSF+ IL-4 induced DC maturation.
Monocyte-DCs were isolated and cultured in the presence of
GM-CSF+ IL-4 (G4) and with or without 25µg/ml C1q (A–C). For the dose
response experiments several concentrations of C1q were added as
indicated (D). Cells were collected on the days indicated and analyzed for
the expression of CD86, CD83, and CD11c for each condition (A–C), or
alternatively, on day 2 HLA-DR analyses were performed for all C1q doses
(D). (A) C1q significantly decreased CD86 expression in monocyte-DCs
compared to G4, *p<0.05, **p< 0.01 (n=4); (B) monocyte-DCs cultured
in the presence of C1q showed a decrease in the percentage of CD83+
cells in comparison with cells cultured in G4 alone. While CD83 expression
was detected on the surface of these cells, their MFI remained low
throughout the days with or without the addition of C1q (data not shown),
*p<0.05 (n=4); (C) CD11c expression was increased by day 2 with the
addition of C1q compared to day 0. There was no significant difference in
CD11c expression levels on cells cultured with or without C1q (n=6);
(D) dose response analysis revealed that the MFI of HLA-DR+ cells
correlates negatively with increasing doses of C1q on day 2. While there
was little or no difference in the distribution of HLA-DR on the cells at lower
doses (10–25µg/ml), at higher doses decreased expression was noted
(MFI) (n=3). Cells were gated on DR+ cells for all experiments [adapted
from Ref. (35)].
mono-DCs when they are cultured in the presence of C1q (35),
signaling blockades that may potentially be mediated by CD14
should be evaluated. LPS triggers CD14/TLR4 mediated signal-
ing to induce cell differentiation via TRAF6 and IRAK4 signaling.
Although the effect of C1q on CD14− and TLR-mediated sig-
naling cascades in mono-DCs has not been yet fully investigated,
ligand engagement of gC1qR (HCV core protein and mAb) has
been shown to increase PI3K activation and Akt phosphoryla-
tion in LPS stimulated monocytes in an ERK independent manner
(64). Moreover, DC-SIGN, which forms a molecular complex with
C1q and gC1qR on the surface of iDCs (30), has been shown to
increase phosphorylation of Raf-1 on Ser338 and Tyr340/341 in a
ligand-dependent manner (65). Furthermore, stimulation of DC-
SIGN with the mannose receptor-1 (MR-1) Ab has been shown to
induce activation of the MEK/ERK kinase cascade (66). Whether
direct stimulation of C1q participates in these signaling pathways,
however, still remains to be investigated.
CONCLUDING REMARKS AND FUTURE OUTLOOK
The present paper is intended to provoke a debate and inject novel
insights into the endlessly intriguing question: Why does homozy-
gous deficiency in C1q predispose an individual to develop SLE and
other autoimmune diseases? Although the contribution of C1q to
the process of apoptotic cell clearance is unquestionable – and
is supported by robust experimental data – the presence of
functionally redundant pathways for removal of apoptotic bod-
ies together with the direct effect of C1q on monocytes/DCs and
T cells would suggest that, in addition to its role in apoptotic
clearance, locally secreted C1q – which is DC maturation depen-
dent – determines the activation thresholds of B and T cells and
that C1q deficiency causes incomplete maintenance of peripheral
tolerance. Therefore, while in the steady state, C1q would regu-
late cells during the early DC differentiation events by silencing
critical phagocytic or stimulatory markers requisite for antigen
presentation (innate immunity), recognition of “danger” would,
on the other hand, impart a signal that drives monocytes toward
the DC lineage (adaptive immunity). Deficiency in C1q there-
fore will disrupt this equilibrium. In addition, in the absence of
danger signals, C1q may help maintain steady state conditions by
skewing DC differentiation toward a “hybrid” cell type with both
monocyte–macrophage-like (increased CD14, enhanced phagocy-
tosis, IFN-γ secretion) and DC-like (T cell priming) characteris-
tics. The distinct binding orientation of C1q (heads versus tail)
on the monocytes and iDCs also suggests that specific C1q/C1qR
interactions – and possibly other surface molecules – may reg-
ulate cells as they transition from the monocyte state toward
the professional APC state. The presence of C1q together with
C1r, C1s, and C1-INH on the monocyte surface with its versatile
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antigen-capturing region displayed outwardly also supports the
concept that monocytes may represent the first sentinels of danger
in the blood.
However, although these postulates are conceptually appeal-
ing and are supported by experimental data, future studies, which
focus on the role of C1qRs, C1q, and C1 within the microenvi-
ronment of the monocyte/DC–antigen encounter will be neces-
sary if we are to gain insight into why deficiency in any of the
components of C1 leads to the development of autoimmunity.
More importantly, information derived from such studies will not
only provide new groundwork for future undertakings related to
innate and acquired immunity, but also would give credence to
targeted modulation of C1/C1q-mediated DC function as new
treatment option aiming at alleviating DC-driven autoimmune
responses.
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